Chairman - David Mace has extensive international plc board experience (AIM and Main Market), having been both a NED and NEC on companies including Center Parcs (UK) PLC and GW Pharmaceuticals PLC. He has much experience of developing privately and VC supported businesses through key growth rounds and IPO. David is a seasoned individual with an excellent track record of proactive strategic board direction, including growing and developing successful businesses internationally in a wide variety of business sectors, particularly developing added value capability to land development projects in territories as diverse as the Caribbean and New Zealand.
David has a BSC in Biological Sciences from Heriot Watt University and is a graduate of the Advanced Management Programme at Harvard Business School. He brings considerable leadership skills, development experience and global marketing vision to the team. David lives in Dorset with his wife and has three grown up children.
Chief Executive Officer - Martin Waddell's first career was in sales, marketing & advertising roles including corporate and agency side positions. He then trained as a commercial and intellectual property lawyer and worked in-house within the university sector, leading the commercialisation of a number of high technology licensing opportunities and spin-outs, including Advanced Gel Technology and Cybersense Bio-Systems. He has extensive experience of developing such companies across a broad range of sciences and created and formed the Cascade Venture Capital Seed Fund in 2001. Since 2002 he has been in private practice consultancy, working in areas of media, new technology and start up development. This included leading a joint venture for BT Global Services and Pierhouse Group and business development with Cambridge "High Tech's" such as Cambridge Visual Networks, recently leading the roll out of a new Broadband and Satellite Service in the UK for Eurona PLC of Spain.
He lives in Edinburgh with his wife and 4 children after spending many years in the Languedoc - France as a regulated French IFA and developing much of the agricultural and plant knowledge that underpins our strategy.
We work to bring solutions to healthcare problems by utilising natural plant growing methodologies that reduce the cost of plant extracts and their related drugs. By doing this, we can make existing and new pharmacy compounds and food health supplements affordable to a wider base of the global healthcare population. Combining this with rigorous research allows us to identify and create value opportunities for our investors that broaden the scope of their portfolios and are crucially, uncorrelated to the markets.